| Publikationstyp: | Konferenz: Poster |
| Art der Begutachtung: | Peer review (Abstract) |
| Titel: | Is there an impact of early initiation of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis in the German registry? |
| Autor/-in: | Braune, Stefan Drewek, Anna Bergmann, Arnfin Schuler, Maximilian Ait-Tihyaty, Maria H Le, Hoa Keenan, Alex Gandhi, Kavita van Denderen, Jacqueline |
| et. al: | No |
| Angaben zur Konferenz: | 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, The Netherlands, 26-28 Oktober 2022 |
| Erscheinungsdatum: | Okt-2022 |
| Sprache: | Englisch |
| Fachgebiet (DDC): | 615: Pharmakologie und Therapeutik 616.8: Neurologie und Krankheiten des Nervensystems |
| Zusammenfassung: | Aim: To compare the characteristics and outcomes of patients who initiate disease modifying treatments (DMTs) early compared to later over a 5-year period. Methods: Data came from NeuroTransData (NTD) MS registry run by a network of Germany-wide neurologists. Study included patients initiating DMTs between Jan 1, 2009, and Oct 1, 2021. Patient cohorts were defined based on the time of initiation of their first DMT relative to the date of RRMS diagnosis: Cohort 1 (<=12 months n=5048), Cohort 2 (> 12 months to <= 24 months, n=559), Cohort 3 (> 24 months to < 5 years, n=788), and Cohort 4 treatment (more than 5 years, n=1604). Results: There were no meaningful differences in age, time since symptoms manifestation, or EDSS across the cohorts at time of first DMT initiation (index). Relapse activity appeared to be a leading reason for DMT initiation with at least one relapse experienced 1-year pre-index by 43.6% patients in cohort 1 compared to 31.3%, 27.2% and 18.1% of patients in cohorts 2,3,4, respectively. Glatiramer acetate/interferons were most used in cohort 1 (74.4%) and least in cohort 4 (54.5%). The use of other DMTs, including monoclonal antibodies, increased with delayed time to DMT initiation. For cohorts 1 and 2, average (SD) annual relapse rate (ARR) was 0.4 (0.6) and 0.3 (0.6) at year 1 but declined to 0.08 (0.3) and 0.1 (0.3) by year 5, respectively. In vontrast, average ARR mean (SD) was in a narrow range for cohorts 3 [0.1 (0.4)- 0.2 (0.5)] and 4 [0.05 (0.2)-0.1 (0.3)] through the study period. EDSS for patients delaying DMTs numerically worsened than those who initiated early over 5 years [e.g., mean (SD) worsening from 1.3 (1.1) at year 1 to 1.9 (1.6) at year 5 in cohort 3 compared to stable EDSS of 1.5 over 5 years in cohort 1]. EDSS results must be interpreted with caution due to high level of missingness. Conclusions: Neurologists appear to make a reasonable prognosis regarding potential changes in patients’ EDSS status over a 5-year period and whether to initiate treatment or wait and see clinical changes. A potential trade-off with the wait and see approach is that more efficacious treatments are used as initial therapy. Nevertheless, the benefit: risk of such treatments may be an important consideration along with other disease-related factors in individualizing patient treatment decisions. |
| URI: | https://digitalcollection.zhaw.ch/handle/11475/26177 |
| Volltext Version: | Publizierte Version |
| Lizenz (gemäss Verlagsvertrag): | Keine Angabe |
| Departement: | School of Engineering |
| Organisationseinheit: | Institut für Datenanalyse und Prozessdesign (IDP) |
| Publiziert im Rahmen des ZHAW-Projekts: | Therapievergleich für Multiple Sklerose |
| Enthalten in den Sammlungen: | Publikationen School of Engineering |
Dateien zu dieser Ressource:
Es gibt keine Dateien zu dieser Ressource.
Zur Langanzeige
Braune, S., Drewek, A., Bergmann, A., Schuler, M., Ait-Tihyaty, M., H Le, H., Keenan, A., Gandhi, K., & van Denderen, J. (2022, October). Is there an impact of early initiation of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis in the German registry? 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, the Netherlands, 26-28 Oktober 2022.
Braune, S. et al. (2022) ‘Is there an impact of early initiation of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis in the German registry?’, in 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, The Netherlands, 26-28 Oktober 2022.
S. Braune et al., “Is there an impact of early initiation of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis in the German registry?,” in 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, The Netherlands, 26-28 Oktober 2022, Oct. 2022.
BRAUNE, Stefan, Anna DREWEK, Arnfin BERGMANN, Maximilian SCHULER, Maria AIT-TIHYATY, Hoa H LE, Alex KEENAN, Kavita GANDHI und Jacqueline VAN DENDEREN, 2022. Is there an impact of early initiation of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis in the German registry? In: 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, The Netherlands, 26-28 Oktober 2022. Conference poster. Oktober 2022
Braune, Stefan, Anna Drewek, Arnfin Bergmann, Maximilian Schuler, Maria Ait-Tihyaty, Hoa H Le, Alex Keenan, Kavita Gandhi, and Jacqueline van Denderen. 2022. “Is There an Impact of Early Initiation of Disease-Modifying Therapies in Patients with Relapsing-Remitting Multiple Sclerosis in the German Registry?” Conference poster. In 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, the Netherlands, 26-28 Oktober 2022.
Braune, Stefan, et al. “Is There an Impact of Early Initiation of Disease-Modifying Therapies in Patients with Relapsing-Remitting Multiple Sclerosis in the German Registry?” 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Amsterdam, the Netherlands, 26-28 Oktober 2022, 2022.
Alle Ressourcen in diesem Repository sind urheberrechtlich geschützt, soweit nicht anderweitig angezeigt.